t-AUCB

t-AUCB, also known as trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid, is a potent, orally active, and selective small molecule inhibitor of soluble epoxide hydrolase (sEH). Developed in the laboratory of Dr. Bruce Hammock, its primary mechanism involves preventing the degradation of beneficial epoxyeicosatrienoic acids (EETs), thereby increasing their endogenous levels. This leads to a range of potential therapeutic effects, including the attenuation of renal fibrosis, protection against ischemia reperfusion injury, promotion of brown adipogenesis, and anti-glioma activity. It also modulates cholesterol balance and improves vascular endothelial dysfunction in hypertension, often through downstream pathways involving PPARγ, NF-κB-p65, and AMPK/UCP2.

Other names

trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid